drugset / Trial / NCT00006054
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Terminated
Fairview University Medical Center
Treatment
Summary
OBJECTIVES: I. Provide curative immunoreconstituting allogeneic bone marrow transplantation for patients with primary immunodeficiencies. II. Determine relevant outcomes of this treatment in these patients including quality of survival, extent of morbidity and mortality from complications of the treatment (e.g., graft versus host disease, regimen related toxicities, B- cell lymphoproliferative disease), and completeness of functional immunoreconstitution.
Timeline
- Start
- 2000-03
- Primary completion
- 2002-12
- Completion
- 2002-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | Intravenous |
| Subject | Busulfan | Small molecule | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Cyclosporine | Peptide | — | Intravenous |
| Subject | Etoposide | Small molecule | — | Intravenous |
| Subject | Methylprednisolone | Other / unclassified | — | Intravenous |
| Subject | Prednisone | Other / unclassified | — | Oral |
| Background | Methotrexate | Small molecule | — | Intravenous |